Antibiotic resistance could help find drugs for some of the most intractable diseases.

December 14, 2015

Amyloid diseases such as Parkinson's, Alzheimer's and type-2 diabetes pose a particular problem for drug designers because they do not present a clear target structure to aim at.

Instead of the disease being linked to a single, easily identifiable species such as the active site of an enzyme or a specific receptor, amyloid diseases are associated with heterogeneous accumulations of proteins sticking together.

This is the key reason why many amyloid diseases are currently incurable.

The new study, published in Nature Chemical Biology, outlines a way of using antibiotic resistance to find chemicals capable of stopping amyloid formation.

Professor Sheena Radford, FRS Director of the Astbury Centre for Structural Molecular Biology at the University of Leeds, led the research.

She said: "Until now, we haven't had effective ways to identify drugs to combat amyloid formation. Amyloid-prone proteins often don't have a clearly defined structure, which makes it very difficult to identify areas to target with drugs.

"Also, because amyloid-causing proteins have a tendency to stick together, they can be very hard to study in the lab. This study shows a way of getting around these problems by grafting amyloid-prone sequences into enzymes which break down antibiotics."

The study, involving researchers in the University's School of Chemistry and the Astbury Centre for Structural Molecular Biology, exploits the complex series of adversarial relationships between molecules in a positive way to select for chemicals that counter amyloid formation.

First, amyloid-prone sequences from target proteins are attached to antibiotic degrading beta-lactamase enzymes. Bacteria carrying the modified enzymes are combined in laboratory dishes with the antibiotic. Normally, the presence of the beta-lactamase would disable the antibiotic, allowing bacterial growth.

However, the amyloid-causing sequences act as "Trojan horses" in the beta-lactamase, preventing it from attacking the antibiotic and therefore stopping the tell-tale bacterial growth. Next, the researchers add chemicals and test whether they disable the amyloid-causing sequences, freeing the beta-lactamase to attack the antibiotic and allowing bacterial growth.

Dr Janet Saunders, a researcher on the study, said: "In our research, an old enemy -- anti-bacterial resistance -- turns out to be our friend. When we see bacterial growth, we know we have chemicals that are obstructing amyloid formation."

The study identified one chemical -- L-dopamine -- that blocks amyloid deposits forming from sequences associated with type II diabetes. However, the real significance of the work is its potential for generic use with any protein associated with amyloid disease.

Co-author Dr David Brockwell, Associate Professor in the University's School of Molecular and Cellular Biology, said: "If you can insert a protein sequence into beta-lactamase, you are likely to be able to use this technique as a screen for chemicals capable of inhibiting its aggregation. You can screen thousands of compounds by putting them through this test."

Professor Radford said: "It is important to stress that an efficient screen is only one step in the journey toward drug discovery. The power of our study is that it provides the first step on this path by showing us the type of molecules we should be looking at to inhibit a particular disease-causing protein."

Another application of the new technique could be for use in the manufacture of bio-pharmaceuticals, a class of protein-based drugs that includes many of the highest grossing modern drugs.

Dr Brockwell said: "The problem with many of these new protein-based drugs is that they suffer from similar problems to those we see in amyloid diseases; they stick together. This means you can end up with potentially life-saving drugs that you cannot manufacture.

"We are investigating whether we can use our technique to work out which biopharmaceuticals will be resistant to aggregation and hence much more likely to be successful as a drug product."
The research was funded through a Biotechnology and Biological Sciences Research Council (BBSRC) industrial CASE partnership with University of Leeds spinout Avacta Group, an AIM-listed company dedicating to providing transformational tools to life scientists.

Innovate UK and the BBSRC have provided additional funding to explore the technique's use with bio-pharmaceuticals.

The Astbury Centre for Structural Molecular Biology at the University of Leeds is one of Europe's leading centres for structural biology.

Its research looks at biological structures at an atomic level and is vital to finding new ways to deal with biomedical challenges including ageing, cancer, heart disease and drug resistance.

The Astbury Centre recently received a £17 million investment from the University in the new Astbury BioStructure Laboratory, equipped with world-class electron microscopy and nuclear magnetic resonance facilities.

The centre has a grant portfolio of over £50 million from funders including the Wellcome Trust, the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC), the Engineering and Physical Sciences Research Council (EPSRC), the European Research Council (ERC), British Heart Foundation, Cancer Research UK, Yorkshire Cancer Research, and The Bill and Melinda Gates Foundation.

Further information

Professor Radford and Dr Brockwell are available for interview.


University of Leeds Press Office

The full paper is available on request.

University of Leeds

Related Antibiotic Resistance Articles from Brightsurf:

Discovery promising for millions at risk from antibiotic resistance
There is new hope for approximately 700,000 people who die each year from antibiotic resistant infections, with University of Queensland researchers discovering how bacteria share antibiotic-resistance genes.

Pollution linked to antibiotic resistance
Antibiotic resistance is an increasing health problem, but new research suggests it is not only caused by the overuse of antibiotics.

Antibiotic resistance and the need for personalized treatments
Scientists have discovered that the microbiota of each individual determines the maintenance of antibiotic resistant bacteria in the gut: whereas in some individuals resistant bacteria are quickly eliminated, in others they are not.

One of the mechanisms of Staphylococcus antibiotic resistance deciphered
The Russian side is represented by Structural Biology Lab (Kazan Federal University) and Institute of Proteins (Russian Academy of Sciences).

Antibiotic-resistance in Tanzania is an environmental problem
WSU study finds that environmental transmission rather than antibiotic use explains the presence of antibiotic-resistant bacteria in people, domestic animals and wildlife.

Stressed-out dust is sharing antibiotic resistance genes
A new Northwestern University study is the first to find that bacteria living in household dust can spread antibiotic resistance genes.

Cause of antibiotic resistance identified
Bacteria can change form in human body, hiding the cell wall inside themselves to avoid detection.

The solution to antibiotic resistance could be in your kitchen sponge
Researchers from the New York Institute of Technology (NYIT) have discovered bacteriophages, viruses that infect bacteria, living in their kitchen sponges.

Antibiotic resistance in spore-forming probiotic bacteria
New research has found that six probiotic Bacillus strains are resistant to several antibiotics.

How bacteria acquire antibiotic resistance in the presence of antibiotics
A new study's disconcerting findings reveal how antibiotic resistance is able to spread between bacteria cells despite the presence of antibiotics that should prevent them from growing.

Read More: Antibiotic Resistance News and Antibiotic Resistance Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to